Focus research 2022 MELASPHINX team
Discovery of new biomarkers of resistance to melanoma immunotherapies
The team showed that neutralization of TNFα, a major inflammatory cytokine, potentiates the response to anti-PD-1 in murine models of melanoma. This work underpins the scientific rationale for the TICIMEL clinical trial (NTC03293784), which aims to evaluate the safety, tolerability and anti-tumor activity of anti-TNFα molecules (certolizumab or infliximab) in combination with ipilimumab and nivolumab in patients with advanced melanoma. Initial results are promising, with signs of activation and maturation of the immune response, fewer side effects in patients treated with infliximab, and to date a better clinical response rate in the certolizumab-treated cohort. Investigations are ongoing in an expansion cohort.
To find out more about the IUCT-Oncopole and CRCT-Oncopole research focuses, please click here
Toulouse Cancer Research Center (Oncopole)
Toulouse - FR
CRCT-Oncopole Follow 1,433 1,279
Compte officiel du Centre de Recherches en Cancérologie de Toulouse
;
🇬🇧Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells. ImPact team @CordelierPierre article from @crctoncopole published in @CommsBio
➡️https://www.crct-inserm.fr/en/targeting-the-energy-production-process-in-pancreatic-cancer-cells-which-relies-on-an-enzyme-called-cytidine-deaminase-could-make-these-cells-more-vulnerable/
Contact us
+33 5 82 74 15 75
Want to join
the CRCT team ?
